Try our Advanced Search for more refined results
Life Sciences - August, 2012
277 articles
- $12B Nestle-Pfizer Deal Could Impact Formula Market: Regulator
- Hospital Says Baxter Unit Can't Dodge Drug Pump Royalties
- GSK Hits Apotex With Suit Over Bid For Generic Prostate Drug
- Abbott Targets Amneal In Latest Fight Over Generic Niaspan
- Pharmacy Can't Force Cardinal Health To Supply Painkillers
- Upsher-Smith Urges High Court To Hear K-Dur Antitrust Case
- 4 Firms Feared Most By In-House Counsel
- Researchers Fire Back At University In IP, Contract Fight
- Taro's PE Backers Balk At Sun Pharma's $600M Buyout
- Biotech Co. Says BP Unit Conducted Negligent Enzyme Work
- Janssen Loses La. Appeal Of $258M Risperdal Verdict
- Novartis Wins Bone Drug Injury Suit On Timeliness
- FDA Questions Efficacy Of Novartis Inhaled CF Treatment
- High Court Grants Review Of CAFA Dispute
- Wyeth Loses Bid To Toss 2 Fen-Phen Suits
- Judge Guts Medline Suit Seeking Surgical Mesh Coverage
- Apotex, Lupin Hit With Suit Over Generic Arthritis Drug
- CBP Change: The Centers Of Excellence And Expertise
- Wyeth, Schwartz Ask 10th Circ. To Nix Suit Over Generic Reglan
- Sunovion To Lay Down Up To $430M For Elevation Pharma
- FTC Cephalon Case Stayed Pending K-Dur Supreme Court Bid
- Judge Trims Securities MDL Claims Against Merck Execs
- Bristol-Myers Recalls Cancer Drug Due To Overfilled Vial
- Wolters Kluwer Must Face Accutane Case In Pa. Court
- Pfizer Units Triumph In Latest Hormone Therapy Suit
- J&J To Pay States $181M Over Deceptive Risperdal Marketing
- Genmab Lands Potential $1.1B J&J Cancer Drug Deal
- Watson Next Target As Purdue Protects Insomnia Drug Patent
- Novartis Beats Zometa Injury Suit At 2nd Circ.
- Omnicare Skirts FCA Suit Over Anti-Psychotics Prescriptions
- GNC, USPLabs Hit With Suit Over DMAA Supplements' Safety
- Novo Still Owes $3M Over Patent Use Code Row, Caraco Says
- Pliva, Others Escape Generic Reglan Suit Due To Mensing
- Helicos Genetics Patent Ruled Invalid In Illumina Row
- MDL Plaintiffs Say GSK Won't Uphold Avandia Settlement
- Abbott Says Sandoz Marketed Generic Nimbex Too Soon
- FTC May Have To Follow Merck's Lead In Pay-For-Delay Fight
- SEC Sues 8 For Insider Trading In Sanofi, Chattem Deal
- Medex Can't Take Back 347 Emails From Discovery In $7M Suit
- FDA Warns Hospira Over Issues At Costa Rican Plant
- Janssen Again Targets Lupin, Others Over Generic Prezista
- FDA Advisers Back Broader Humira Approval
- UK Removes DMAA Weight-Loss Supplements From Market
- Sun Pharma Unit Back In Action 3 Years After Drug Seizures
- Sanofi's Genzyme Pulls 19 Lots Of Thymoglobulin Vials
- Danisco Targets Novozymes Ethanol-Producing Enzyme Patent
- Novartis Dodges Fraud Claims In Farmers' Pesticide Suit
- Authorized Generics And Pay-For-Delay Settlements
- Merck Moves To Block Generic Ganirelix Fertility Treatment
- Old Claims Off Limits In Supplement Co. CEO's Trial: 9th Circ.
- FDA Puts Idenix Hep C Drug On Hold Amid Bristol-Myers Woes
- Baxter Win Gives Drugmakers A Leg Up In NJ Warning Suits
- Pfizer Failed To Warn Of Azithromycin Side Effects, Suit Claims
- AstraZeneca, Others Hit With Nexium Pay-For-Delay Suits
- Bristol-Myers Sued Over Heart Damage In Hep C Drug Trial
- FDA To Study How Well Consumers Understand Pharma Ads
- Endo Claims No Liability In AMS Pelvic Mesh Implants MDL
- FSMA's Potential Impact, Part 3: Reinspection, Recall Fees
- Profit Counting: The Pfizer FCPA Settlement
- AstraZeneca Reaches $26M Deal With SC In Seroquel Suit
- GAO Backs Philips' Protest Of VA Imaging System Contract
- Merck Asks High Court To Review K-Dur Pay-For-Delay Case
- Method Patent, Lilly Drug Patent Can Coexist, Fed. Circ. Rules
- Chamber Backs Allergan's Appeal Of Controversial Decision
- Bristol Takes $1.8B Hit, Ditches Hepatitis C Drug After Death
- DC Circ. Upholds NIH Stem-Cell Research Funding
- Cipro Buyers Urge Calif. Court To Revive Pay-For-Delay Case
- Pfizer Strikes Deal With Impax Over Generic Detrol LA
- Evanston Wins 5th Circ. Coverage Row In Organ Selling Case
- Horizon Unit Closes $75M Loan For Health, Tech Investments
- Expert Report Sticks In P&G Denture Cream MDL
- EU Agency Demands Cancer Drug Recall Due To Sterility Risks
- FDA Wary Of Wider Use For Abbott's Humira
- What's Making Attorneys Flee Their Firms?
- Purdue Sues Actavis Over Patent For Generic Sleep Drug
- Pfizer Can't Boot Doctors' Suicide Testimony From Chantix MDL
- ViiV, Vertex Sue Over Mylan's Bid To Market Generic Lexiva
- New Context For Application Of State-Of-The-Art Principle
- PPACA: What's Next For Life Sciences Companies
- J&J's DePuy Recalls Joint Implants After FDA Warning Letter
- Pfizer, Others Shake Price-Fixing Appeal From Pharmacies
- Purchaser Class Certified In J&J Blood Test Antitrust MDL
- Pa. High Court Won't Bar Reglan Patients' Claims
- Customers Call Foul On Vitamin Co.'s Cartilage-Healing Claims
- USPTO Can't Dodge Exela Suit Over Patent Revival
- SEC's Conflict Minerals Rules: Strict, Onerous, Vague
- What You Need To Know About Chinese Product Liability Law
- Actavis Sued Over Generic Oleptro Plans
- ArthroCare Execs Arrested Over $400M Stock Drop
- Fed. Circ. Junks Boston Scientific Win In Stent Patent Fight
- Medtronic Fails To Beat Bone Device Claims On Preemption
- Device Co. Sues Over $6M Loss After Tainted Mouthwash Recall
- FDA Warns Generics Makers To Yank Defunct Applications
- Judge Reverses Consolidation Of Bayer FCA Suits
- Hatch-Waxman Safe Harbor: Post-Approval Activity Update
- Cardinal Subpoenaed By DEA, DOJ Over Drug Diversion
- Shire Says Genzyme Can't Prove False Bone Drug Claims
- Shoe Insert Maker Sued Over Whistleblower's Ouster
- Drug, Medical Device Tracking — Will Medications Be Next?
- Generics Safe Harbor Question Could Derail Biosimilars
- Drug Cos. Cut Loose From Darvocet, Darvon MDL Suits
- Merck Sues To Shut Out Watson's Generic Propecia
- FDA Warns Medtronic Unit Over Handling Of User Complaints
- Synthes Bone Putty Recalled Over Fire Risk During Surgery
- Gilead Hits Cipla With Patent Suit Over HIV Drug Emtriva
- Pfizer Tells 1st Circ. Neurontin MDL Shows No Proof Of Harm
- A Therapy For European Patent Term Extensions
- Del. Court Won't Toss Board Election Shareholder Suit
- FDA Ends Ban Of Claris Lifesciences Products
- Nutrition Co. Sues Beazley Over $1M In Hurricane Damages
- Patent Re-Exam Discovery Barred, Abbott Tells Fed. Circ.
- Biotech Exec Settles Over Trades Ahead Of Novartis Deal
- FDA Ties Post-Approval Device Studies To Public Health
- J&J Unit Settles 1st Metal Hip Implant Suit Slated For Trial
- Judge Kills Shareholder Suit Over J&J's $20B Synthes Buyout
- St. John's Settles Contract Suit Over Army Eye Research Deal
- Baseball Hall Of Famer Settles Insider Trading Claims
- US Joins FCA Suit Over Orthotics Co. Billing
- CMS Names New Chief To Implement Key ACA Provisions
- Amgen Ruling Placed Cert. Bar Too Low, Ex-SEC Officials Say
- Cinven To Pay HgCapital £465 Million For Drugmaker Mercury
- 3rd Circ. Keeps K-Dur Ruling In Place As FTC Fights IP Deals
- Bill Bolstering Calif. False Claims Law Heads To Gov.
- Myriad — Under The Microscope
- Medical Industry Fears Device ID Rule Would Drive Up Costs
- J&J Intermediary Drug Rule Case Won't Get 2nd Look
- Patent Law Trumps Policy In Myriad Cancer Gene Decision
- FDA Pushes X-Rays For St. Jude Heart Device Recipients
- Janssen Biotech, NYU Sued Over Neuro Treatment Patents
- J&J, Pfizer, Others Beat Pharmacies' Drug Pricing Suit
- New Patient Rep Law Could Shake Up Drug Review Process
- Senators Want Tighter Rules On Livestock Antibiotics
- Fed. Circ. OKs Myriad's Gene Patents In Light Of Prometheus
- GSK, Teva Say Lamictal IP Licensing Deal Wasn't Conspiracy
- Unveiled: A New Enforcement Method In GSK Settlement
- Reverse Payment Settlements In Pharma Industry: Revisited
- FTC's Pay-For-Delay Push May Hinder Pharma Patent Deals
- Santarus Seeks To Block Dr. Reddy's Generic Zegerid
- US Joins FCA Suit Over Off-Label Vein Treatments
- Lawmakers Urge FDA To Overhaul Medical Device Database
- Class Cert. Sought In Covidien Surgical Stapler Suit
- Codeine Can Be Deadly For Some Children, FDA Warns
- Quigley Ch. 11 Plan Heads To Vote Despite Protests
- HHS Recruits Pharmacies To Tout ACA's Medicare Benefits
- Pfizer Vaccine Decision In Federal Court Bars NJ Suit, Court Says
- Grassley Expands Agency Email-Monitoring Inquiry
- Watson Sues FDA To Regain Exclusivity For Generic Actos
- GSK Keeps Slimming Down With $270M Sale Of Aussie Drugs
- Omnicare Beats Contaminated-Drug FCA Suit
- Faulty Breast Implants Spark UK Cosmetic Surgery Probe
- 4th Circ. Clears Alpharma Of Ex-Sales Rep's Retaliation Claim
- Court Blocks Sale Of Blood Clot Reducer 'Knockoff'
- Bayer Seeks Centralization Of NJ Mirena Litigation
- Quigley, Pfizer Answer Disclosure Statement Objections
- Drug, Device Makers Push For Final Physician Payment Rule
- Roche Worker Axed For Resisting Hasty Cancer Trials, Suit Says
- Icahn Blasts Forest Labs' Nondisclosure Of FDA Letter
- Trademark Must Be Considered As A Whole, Fed. Circ. Rules
- Goodwin Procter Brings Former ITC Atty Into IP Group
- AstraZeneca Looks To Block Generic Pulmicort
- CMS Overpaid $4.6M For Drugs Last Quarter, Report Says
- J&J Unit Escapes FCA Case Over Alleged Procrit Kickbacks
- Drugmakers Freed From Generic Reglan Claims In Tenn. Suits
- Fed. Circ. Revives Jury Verdict In Wake Forest Patent Suit
- FTC's New Rule Zeroes In On More Pharma Patent Deals
- ACA Unlikely to Change Employer Health Coverage, GAO Says
- FTC Rips Wyeth, Teva Arguments In Effexor Antitrust Suit
- Former Hansen Medical VPs Can't Duck SEC's Fraud Claims
- Shearman Reps Sun Pharma In Long-Sought $600M Taro Buyout
- Ga. Medicaid Program Must Buy Brand-Name Makena: Judge
- Irish Drugmaker Elan To Spin Off R&D Business
- Drug Wholesaler Altec Fined $2M In Gray Market Conspiracy
- Establishing The Weight Of Evidence After Sciele
- Callisto Investor Challenges Proposed Synergy Merger
- Ohio Willow's Prosthetic-Cushion Patent Ruled Invalid
- Mensing Can't Keep Bristol-Myers' Plavix Suits Federal
- Vioxx Appeal Imperils Merck MDL Deals, 5th Circ. Hears
- New FDA Guidance Aims To Speed Medical Device Reviews
- Forest Labs To Alter Governance To Settle Derivative Suits
- Ex-China Official's Testimony Lends Boost To Vitamin C Cos.
- Ex-Carlyle Consultant Gets Probation For Insider Trading
- Sequester Could Gum Up FDA Drug, Device Reviews
- Breg Pain Pump Injury Case Revived In 6th Circ.
- Hansen Can't Escape Bulk Of Securities Inflation Class Action
- Hatch-Waxman Safe Harbor's Scope Likely Headed To High Court
- Roche Blockbuster Lucentis Gets FDA Nod For Broader Use
- CR Bard's Faulty Filters Pose Health Risks, Suit Says
- J&J Misrepresented Splenda Health Benefits, Suit Says
- Cumberland Seeks To Block Perrigo's Generic Acetadote
- Smith & Nephew Seeks $2M From Rivals In Noncompete Suits
- US Trustee Rips Pfizer Unit Quigley's Newest Ch. 11 Plan
- GSK Can't Use Prometheus To Nix Classen's Patent Suit
- No Need To Change Regs To Suit Nanotech Drugs: FDA Official
- GSK Hit With Thalidomide Birth Defect Suit
- Orthofix Bribed Doctors To Use Surgical Services, Suit Says
- NJ Court Keeps Some Claims Alive In Cordis Stent Case
- Forest Labs Reps Marketed Daliresp Off-Label, FDA Says
- Fed. Circ. Eyes Roche's Bid To Stop Boniva Generics
- Judge Orders FDA To Launch Livestock Antibiotic Withdrawal
- Stryker Hit With 1st Metal Hip Implant Suit Since Recall
- Judge Potentially Limits Claims in Avandia MDL
- FDA Limits Use Of Stryker's Wingspan Anti-Stroke Stent
- Limitation On Future Patent Protection For Biosimilars?
- K-V Pharma Wins Access To $31M In Cash Collateral
- Ex-Pfizer CEO Kindler Joins Health Care VC Firm Lux
- FDA Admits It Has Yet To Fill In Big Gaps On Biosimilar Regs
- Generics Industry Gets FTC OK For Shortage Prevention Plan
- Novartis Keeps Grip On Eye Drug Patent In Fed. Circ.
- Former Home Diagnostics CEO Admits To Insider Trading
- K-V Bankruptcy May Hurt FDA's Unapproved Drug Initiative
- 2 North China Pharma Units Exit Vitamin C Antitrust MDL
- Patients Say GSK Lyme Disease Vaccine Caused Arthritis
- Neurontin Ruling Would Kill Off-Label Use, 1st Circ. Hears
- Rule-Of-Reason Analysis Of Pay-For-Delay Settlements
- Warner Chilcott To Pay $1B In Dividends Instead Of Sale
- K-V Challenge To FDA's Enforcement Order On Thin Ice: Judge
- Roche Could Wield Fla. Law Ruling In Other Accutane Suits
- Barr Uses Mensing To Escape Generic Accutane Case
- Judge Triples Damages, Bars Sales In Zeiss Lens Patent Suit
- Medicare Contractors Overpaid $1.6M For Cancer Drug: OIG
- Vaccine Buyers Allowed To Bring Antitrust Suit Against Sanofi
- Epstein Lands GE Expert On Health Tech For LA, DC Offices
- BC Partners Puts Up €500M For German Drugmaker
- Proskauer Hires NetBio GC As Patent Partner In NY Office
- Pfizer Will Pay $60M To End Foreign Bribery Probes
- Much Ado About The Crime Of Doing Nothing
- Bankruptcy Judge Grants K-V Pharma Most 1st-Day Motions
- Bristol-Myers Insider Trading Suit Is Compliance Gut Check
- Manufacturer Can't Shake NuAire's Incubator Recall Case
- J&J Win Affirmed In 5th Circ. Mesh Warning Appeal
- CORRECTED: Rival Drug Didn't Infringe Genzyme's Arthritis Patent: Jury
- Pharmas Seek Pay-For-Delay Suit Stay Pending High Court Input
- K-V Files For Ch. 11 As $45M Hologic Bill Comes Due
- Paul Floats Bill To Allow Dying Access To Unapproved Drugs
- 9th Circ. At Odds With Calif. Law In OT Case, Drug Reps Say
- J&J's Birth Control Warnings To Doctors Were Enough: Ruling
- FDA Feedback: New Guidance For Device Applicants
- Avoiding Trade Secret Litigation In The Life Sciences
- Case Study: In Re Boston Scientific
- Nycomed, Others Say Apotex Infringes Nasal Spray Patents
- University Says Cancer Research Team Defected, Stole IP
- JPML Won't Centralize Drug Co-Pay Coupon Class Actions
- New Clinical Trial Reporting Bill Risks Spooking Investors
- High Court Could Upend Rare Post-Mensing Loss For Generics
- SEC Targets Teva In FCPA Compliance Probe
- Bristol-Myers Exec Dug Own Grave With Cover-Up Efforts
- Fed. Circ. Lifts Sales Ban On Generic Lovenox
- Aredia, Zometa MDL Judge Moves To Speed Up Cases
- Certifying Compliance Doesn't Decide FCA Burden, US Says
- 8th Circ. Reopens Suit Over Cymbalta Suicide Risks
- Surgical Robot Injury Suits Against Intuitive Won't Be Merged
- Sanofi Accord Brings Idaho Price-Inflation Haul To $23M
- J&J Settles Risperdal Marketing Claims From DOJ, States
- Sanofi Win Marks Another Step In Drugmakers' Twombly March
- Judge Mulls Stay In Roche's Xeloda Patent Suit Against Teva
- Diet Aid Co.'s Insurance Claim Not Time-Barred, 5th Circ. Told
- Class Says It Was Burned By Misleading Coppertone Ads
- Ostrolenk Faber Loses Bid To Reclaim Fees From Biotech Co.
- US Gets Devices To Market Faster Than Europe, Study Shows
- Sens. Want Detailed Cost-Benefit Studies For New Regs
- Ex-Biosara CEO Sues For Return Of 6M Shares
- Covidien Says AECOM Overcharged On Nuke Cleanup Contract
- Merck Gets Claims Based On Puffery Trimmed From Vioxx Suit
- Bristol-Myers Squibb Exec Accused of Insider Trading
- The Evolving Patent Term Adjustment Landscape
- Polsinelli Pulls Pharmaceutical IP Trio To NY Office
- Medical Device Co. Medeia Accuses Rival Of Lifting Software
- Olympus Tells DOJ Of Possible FCPA Violations In Brazil
- Class Cert. In Bayer Case Threatens Due Process, Group Says
- NJ Court Backs Toss Of NuvaRing Suit Against Organon
- Another Co. Surrenders In Seroquel XR Patent Fight
- DSM Sues Supplier Over Recall Due To Unlisted Milk Allergen
- FDA Finalizes Electronic Registration Rule For Devices
- BMS Sues Mylan For $15M Over Improper HIV Drug Sales
- McDermott Boosts Life Sciences Practice With 2 Attys
- Fired Med. Device Worker Didn't Show Retaliation: 8th Circ.
- Matrixx Investors Get Class Cert. In Suit Over Zicam Effects